Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
Aligos Therapeutics, Inc is a biotechnology business based in the US. Aligos Therapeutics shares (ALGS) are listed on the NASDAQ and all prices are listed in US Dollars. Aligos Therapeutics employs 73 staff and has a market cap (total outstanding shares value) of USD$922 million.
|52-week range||USD$12.82 - USD$37.5099|
|50-day moving average||USD$28.3494|
|200-day moving average||USD$23.3985|
|Wall St. target price||USD$34.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$922 million|
TTM: trailing 12 months
There are currently 1.4 million Aligos Therapeutics shares held short by investors – that's known as Aligos Therapeutics's "short interest". This figure is 4.2% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Aligos Therapeutics shares can be evaluated.
Aligos Therapeutics's "short interest ratio" (SIR) is the quantity of Aligos Therapeutics shares currently shorted divided by the average quantity of Aligos Therapeutics shares traded daily (recently around 73683.855291577). Aligos Therapeutics's SIR currently stands at 18.52. In other words for every 100,000 Aligos Therapeutics shares traded daily on the market, roughly 18520 shares are currently held short.
To gain some more context, you can compare Aligos Therapeutics's short interest ratio against those of similar companies.
However Aligos Therapeutics's short interest can also be evaluated against the total number of Aligos Therapeutics shares, or, against the total number of tradable Aligos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aligos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aligos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0391% of the tradable shares (for every 100,000 tradable Aligos Therapeutics shares, roughly 39 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aligos Therapeutics.
Find out more about how you can short Aligos Therapeutics stock.
We're not expecting Aligos Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.